Brian expresses deep concerns about the insufficient testing of mRNA vaccines, highlighting potential unintended consequences and gene transfer issues. Ahmad questions the motives of large pharmaceutical companies, pondering whether they genuinely overlook safety studies or prioritize profits. The discussion reveals a troubling landscape where regulatory requirements may allow for minimal testing, raising alarms about public safety.
